Silo Pharma, Inc. announced a service agreement with Resyca BV to conduct a drug-device study on its microchip-based nasal spray system for SPC-15, an intranasal treatment for PTSD. This study aims to ...
SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery ...
The company states: “Silo Pharma (SILO) announced promising results from a preclinical study on SPC-15. This new formulation, which targets both the serotonin 5-HT4 receptor, 5-HT4R, and the NMDA ...
Study to test effectiveness of Instructional System Designs (ISD) model for Intranasal SPC-15 ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma (SILO), Inc. (“the Company”), a ...
No new PTSD drug approvals in the U.S. in nearly 25 years; large potential addressable market for SPC-15 worldwide SARASOTA, FL, July 07, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ...
Thursday, Silo Pharma Inc (NASDAQ:SILO) provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD). The ...
(RTTNews) - Silo Pharma, Inc. (SILO), Monday announced positive results from a pre-clinical study of SPC-15 showing potential for the treatment of major depressive disorder, and other severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback